No Data
ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns With EPS Projections, Misses Revenue Estimates
ChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $6 Price Target
ChromaDex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 66.95% HC Wainwright & Co. → $6 Reiterates Buy → Buy 04/09/2024 66.95% Roth MKM $4.25 → $6 Main
ChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersCytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press